Literature DB >> 11275878

Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD.

G Triadafilopoulos1, J K Dibaise, T T Nostrant, N H Stollman, P K Anderson, S A Edmundowicz, D O Castell, M S Kim, J C Rabine, D S Utley.   

Abstract

BACKGROUND: In this multi-center study, the feasibility, safety, and efficacy of radiofrequency (RF) energy delivery to the gastroesophageal junction (GEJ) for the treatment of gastroesophageal reflux disease (GERD) were investigated.
METHODS: Forty-seven patients with classic symptoms of GERD (heartburn and/or regurgitation), a daily anti-secretory medication requirement, and at least partial symptom response to drugs were enrolled. All patients had pathologic esophageal acid exposure by 24-hour pH study, a 2 cm or smaller hiatal hernia, grade 2 or less esophagitis, and no significant dysmotility or dysphagia. RF energy was delivered with a catheter and thermocouple-controlled generator to create submucosal thermal lesions in the muscle of the GEJ. GERD symptoms and quality of life were assessed at 0, 1, 4, and 6 months with the short-form health survey (SF-36). Anti-secretory medications were withdrawn 7 days before each assessment of symptoms and pH/motility study. Medication use, endoscopic findings, esophageal acid exposure, and motility were assessed at 0 and 6 months.
RESULTS: Thirty-two men and 15 women underwent treatment. At 6 months there were improvements in the median heartburn score (4 to 1, p < or = 0.0001), GERD score (26 to 7, p < or = 0.0001), satisfaction (1 to 4, p < or = 0.0001), mental SF-36 (46.2 to 55.5, p = 0.01), physical SF-36 (41.1 to 51.9, p < or = 0.0001), and esophageal acid exposure (11.7% to 4.8%, p < or = 0.0001). Esophagitis was present in 25 patients before treatment (15 grade 1 and 10 grade 2) and 8 had esophagitis at 6 months (4 grade 1 and 4 grade 2, p = 0.005). At 6 months, 87% no longer required proton pump inhibitor medication. There was no significant change in median lower esophageal sphincter pressure (14.0 to 12.0 mm Hg, p = 0.19), peristaltic amplitude (64 to 66 mm Hg, p = 0.71), or lower esophageal sphincter length (3.0 to 3.0, p = 0.28). There were 3 self-limited complications (fever for 24 hours, odynophagia lasting for 5 days, and a linear mucosal injury that was healed after 3 weeks).
CONCLUSION: RF energy delivery significantly improved GERD symptoms, quality of life, and esophageal acid exposure while eliminating the need for anti-secretory medication in the majority of patients with a heterogeneous spectrum of clinical disease severity but with minimal active esophagitis or hiatal hernia.

Entities:  

Mesh:

Year:  2001        PMID: 11275878     DOI: 10.1067/mge.2001.112843

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  27 in total

Review 1.  Endoscopic therapies for gastroesophageal reflux disease.

Authors:  George Triadafilopoulos
Journal:  Curr Gastroenterol Rep       Date:  2002-06

2.  Endoscopic treatment of gastroesophageal reflux disease--fact or fancy?

Authors:  Jean Paul Galmiche; Jérôme Barouk
Journal:  Curr Gastroenterol Rep       Date:  2002-06

3.  [Endoscopic therapy of gastroesophageal reflux. Indications, first results].

Authors:  K Caca; B Schumacher; H Neuhaus
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

Review 4.  Endoscopic antireflux therapy.

Authors:  K H Fuchs; S M Freys
Journal:  Surg Endosc       Date:  2003-05-06       Impact factor: 4.584

Review 5.  Endoluminal treatment of GERD--role in contemporary clinical practice.

Authors:  John K DiBaise; Dmitry Oleynikov
Journal:  MedGenMed       Date:  2004-08-04

6.  Endoscopic treatment for gastroesophageal reflux disease: should you learn the techniques?

Authors:  Julia J Liu
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

7.  Paradigm shift in the management of gastroesophageal reflux disease.

Authors:  William O Richards; Hugh L Houston; Alfonso Torquati; Leena Khaitan; Michael D Holzman; Kenneth W Sharp
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

Review 8.  Whither surgery in the treatment of gastroesophageal reflux disease (GERD)?

Authors:  David R Urbach; Wendy J Ungar; Linda Rabeneck
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

9.  Transurethral delivery of radiofrequency energy for tissue micro-remodeling in the treatment of stress urinary incontinence.

Authors:  Mariano Sotomayor; Guillermo Feria Bernal
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-09-12

Review 10.  Endoscopic therapy for GERD: does it have a future?

Authors:  Marvin Ryou; Christopher C Thompson
Journal:  Curr Gastroenterol Rep       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.